Cargando…
Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders
The use of convalescent plasma (CP) from individuals recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising therapeutic modality for the coronavirus disease 2019 (COVID-19). CP has been in use for at least a century to provide passive immunity against a number of...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Atlantis Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486975/ https://www.ncbi.nlm.nih.gov/pubmed/34820612 http://dx.doi.org/10.2991/chi.k.210403.001 |
_version_ | 1784577857537703936 |
---|---|
author | Lanza, Francesco Agostini, Vanessa Monaco, Federica Passamonti, Francesco Seghatchian, Jerard |
author_facet | Lanza, Francesco Agostini, Vanessa Monaco, Federica Passamonti, Francesco Seghatchian, Jerard |
author_sort | Lanza, Francesco |
collection | PubMed |
description | The use of convalescent plasma (CP) from individuals recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising therapeutic modality for the coronavirus disease 2019 (COVID-19). CP has been in use for at least a century to provide passive immunity against a number of diseases, and was recently proposed by the World Health Organization for human Ebola virus infection. Only a few small studies have so far been published on patients with COVID-19 and concomitant hematological malignancies (HM). The Italian Hematology Alliance on HM and COVID-19 has found that HM patients with COVID-19 clinically perform more poorly than those with either HM or COVID-19 alone. A COVID-19 infection in patients with B-cell lymphoma is associated with impaired generation of neutralizing antibody titers and lowered clearance of SARS-CoV-2. Treatment with CP was seen to increase antibody titers in all patients and to improve clinical response in 80% of patients examined. However, a recent study has reported impaired production of SARS-CoV-2-neutralizing antibodies in an immunosuppressed individual treated with CP, possibly supporting the notion of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. This may limit the efficacy of CP treatment in at least some HM patients. More recently, it has been shown that CP may provide a neutralising effect against B.1.1.7 and other SARS-CoV-2 variants, thus expanding its application in clinical practice. More extensive studies are needed to further assess the use of CP in COVID-19-infected HM patients. |
format | Online Article Text |
id | pubmed-8486975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Atlantis Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-84869752021-11-23 Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders Lanza, Francesco Agostini, Vanessa Monaco, Federica Passamonti, Francesco Seghatchian, Jerard Clin Hematol Int Review The use of convalescent plasma (CP) from individuals recovered from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a promising therapeutic modality for the coronavirus disease 2019 (COVID-19). CP has been in use for at least a century to provide passive immunity against a number of diseases, and was recently proposed by the World Health Organization for human Ebola virus infection. Only a few small studies have so far been published on patients with COVID-19 and concomitant hematological malignancies (HM). The Italian Hematology Alliance on HM and COVID-19 has found that HM patients with COVID-19 clinically perform more poorly than those with either HM or COVID-19 alone. A COVID-19 infection in patients with B-cell lymphoma is associated with impaired generation of neutralizing antibody titers and lowered clearance of SARS-CoV-2. Treatment with CP was seen to increase antibody titers in all patients and to improve clinical response in 80% of patients examined. However, a recent study has reported impaired production of SARS-CoV-2-neutralizing antibodies in an immunosuppressed individual treated with CP, possibly supporting the notion of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. This may limit the efficacy of CP treatment in at least some HM patients. More recently, it has been shown that CP may provide a neutralising effect against B.1.1.7 and other SARS-CoV-2 variants, thus expanding its application in clinical practice. More extensive studies are needed to further assess the use of CP in COVID-19-infected HM patients. Atlantis Press 2021-04-16 /pmc/articles/PMC8486975/ /pubmed/34820612 http://dx.doi.org/10.2991/chi.k.210403.001 Text en © 2021 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ). |
spellingShingle | Review Lanza, Francesco Agostini, Vanessa Monaco, Federica Passamonti, Francesco Seghatchian, Jerard Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders |
title | Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders |
title_full | Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders |
title_fullStr | Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders |
title_full_unstemmed | Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders |
title_short | Therapeutic Use of Convalescent Plasma in COVID-19 Infected Patients with Concomitant Hematological Disorders |
title_sort | therapeutic use of convalescent plasma in covid-19 infected patients with concomitant hematological disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486975/ https://www.ncbi.nlm.nih.gov/pubmed/34820612 http://dx.doi.org/10.2991/chi.k.210403.001 |
work_keys_str_mv | AT lanzafrancesco therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders AT agostinivanessa therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders AT monacofederica therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders AT passamontifrancesco therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders AT seghatchianjerard therapeuticuseofconvalescentplasmaincovid19infectedpatientswithconcomitanthematologicaldisorders |